References:
1. Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, et
al. 2017. The clinical spectrum of Erdheim-Chester disease: an
observational cohort study. Blood Adv. 14;1(6):357–66.
2. Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, et al.
2019. The Mayo Clinic Histiocytosis Working Group Consensus Statement
for the Diagnosis and Evaluation of Adult Patients With Histiocytic
Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and
Rosai-Dorfman Disease. Mayo Clin Proc. 94(10):2054–71.
3. Chester W. 1930. Über Lipoidgranulomatose. Virchows Arch Für Pathol
Anat Physiol Für Klin Med. 279(2):561–602.
4. Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed
MR, et al. 2018. The histopathology of Erdheim–Chester disease: a
comprehensive review of a molecularly characterized cohort. Mod Pathol.
31(4):581–97.
5. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al.
2016. Revised classification of histiocytoses and neoplasms of the
macrophage-dendritic cell lineages. Blood. 127(22):2672–81.
6. Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Néel A, et
al. 2014. Association of both Langerhans cell histiocytosis and
Erdheim-Chester disease linked to the BRAFV600E mutation. Blood.
124(7):1119–26.
7. Ozkaya N, Dogan A, Abdel-Wahab O.2017. Identification and targeting
of kinase alterations in histiocytic neoplasms. Hematol Oncol Clin North
Am.31(4):705–19.
8. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, et
al. 2020.Erdheim-Chester disease: consensus recommendations for
evaluation, diagnosis, and treatment in the molecular era.
Blood.135(22):1929–45.
9. Haroche J, Cohen-Aubart F, Amoura Z.2020. Erdheim-Chester disease.
Blood. 16;135(16):1311–8.
10. Pan A, Doyle T, Schlup M, Lubcke R, Schultz M.2011. Unusual
manifestation of Erdheim-Chester disease. BMC Gastroenterol.11(1):77.
11. Villatoro-Villar M, Bold MS, Warrington KJ, Crowson CS, Goyal G,
Shah M, et al. 2018.Arterial involvement in Erdheim–Chester disease: A
retrospective cohort study. Medicine (Baltimore).97(49):e13452.
12. Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V,
Charlotte F, et al. 2018.Phenotypes and survival in Erdheim-Chester
disease: Results from a 165-patient cohort. Am J Hematol.93(5):e114–7.
13. Wang J, Wang F, Sun J, Liang Z, Li J, Zhou D, et al.2021. Pulmonary
manifestations of Erdheim–Chester disease: clinical characteristics,
outcomes and comparison with Langerhans cell histiocytosis. Br J
Haematol.194(6):1024–33.
14. Pulmonary involvement in Erdheim‐Chester disease: A single‐center
study of thirty‐four patients and a review of the literature. [cited
2022 Apr 28]; Available from:
https://onlinelibrary.wiley.com/doi/10.1002/art.27672
15. Binyousef RF, Al-gahmi AM, Khan ZR, Rawah E. 2017.A rare case of
Erdheim-Chester disease in the breast. Ann Saudi Med. 37(1):79–83.
16. Cao X xin, Niu N, Sun J, Cai H, Wang F dan, Wang Y ning, et al.
2019. Clinical and positron emission tomography responses to long-term
high-dose interferon-α treatment among patients with Erdheim–Chester
disease. Orphanet J Rare Dis. 14(1):11.
17. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS. 2017.
Clinical and Radiologic Responses to Cladribine for the Treatment of
Erdheim-Chester Disease. JAMA Oncol. 3(9):1253.
18. Cohen-Aubart F, Maksud P, Saadoun D, Drier A, Charlotte F, Cluzel P,
et al. 2016. Variability in the efficacy of the IL1 receptor antagonist
anakinra for treating Erdheim-Chester disease. Blood. 127(11):1509–12.
19. Goyal G, Shah MV, Call TG, Litzow MR, Wolanskyj-Spinner AP, Koster
MJ, et al. 2018. Efficacy of biological agents in the treatment of
Erdheim-Chester disease. Br J Haematol. 183(3):520–4.
20. Goyal G, Shah MV, Call TG, Hook CC, Hogan WJ, Go RS. 2017. Clinical
and radiological responses to oral methotrexate alone or in combination
with other agents in Erdheim-Chester disease. Blood Cancer J. 7(12):647.